8-K: Abpro Submits IND for HER2-Positive Cancer Drug

Abpro Holdings and Celltrion submitted an Investigational New Drug application to the FDA for ABP-102/CT-P72, a T cell engager for HER2-positive cancers.

Summary

• Abpro Holdings, Inc., in collaboration with Celltrion, Inc., submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ABP-102/CT-P72.
• ABP-102/CT-P72 is a HER2-CD3 T cell engager engineered for optimized CD3 and HER2 binding to improve tumor selectivity, targeting HER2-positive cancers including breast and gastric cancers.
• This IND submission aims to support the initiation of a phase 1 clinical trial, which is anticipated to begin in the first half of 2026.
• Preclinical studies for ABP-102/CT-P72 demonstrated selective activity in HER2-high tumor models and lower activity on cells with normal-tissue-level HER2 expression.
• In non-human primates, ABP-102/CT-P72 was well tolerated, supporting the potential for a favorable therapeutic index in clinical studies.
• This marks Abpro's first IND submission for a phase 1 trial in a solid tumor indication.

Sentiment

Score: 7

Explanation: The IND submission is a significant positive milestone in drug development, indicating progress towards clinical trials. Preclinical data is promising, and the collaboration with Celltrion adds credibility. However, it's still very early stage (Phase 1), and significant risks remain, warranting a moderately positive score.

Positives

• Submission of an IND application for ABP-102/CT-P72, advancing the drug candidate towards clinical trials.
• Preclinical studies demonstrated enhanced HER2-high tumor selectivity and a favorable safety profile for ABP-102/CT-P72.
• The drug was well tolerated in non-human primates, supporting a potential favorable therapeutic index.
• Represents Abpro's first IND submission for a phase 1 trial in a solid tumor indication, expanding its immuno-oncology pipeline.
• Highlights a productive co-development collaboration between Abpro and Celltrion.

Risks

• The timing and advancement of development programs are subject to risks and uncertainties.
• Abpro's ability to continue as a going concern is not guaranteed.
• Abpro's ability to achieve compliance with Nasdaq listing standards remains a factor.
• Expectations regarding the therapeutic benefit of Abpro's programs may not be realized.
• Final data from preclinical studies and completed clinical trials may differ materially from reported interim data.
• Abpro's ability to efficiently discover and develop product candidates is subject to various challenges.
• Abpro's ability to obtain and maintain regulatory approval of product candidates is uncertain.
• Abpro's ability to maintain its intellectual property is crucial for its business model.
• Risks are associated with the implementation of Abpro's business model, including strategic plans for its business and product candidates.

Future Outlook

Pending regulatory clearance, a phase 1 clinical trial for ABP-102/CT-P72 is anticipated to begin in the first half of 2026 in patients with HER2-positive cancers. The planned study will evaluate the safety, pharmacokinetics, and preliminary efficacy of ABP-102/CT-P72 in a dose-escalation and dose-expansion format. Data generated from the trial will inform dose selection and guide subsequent clinical development.

Management Comments

• "We are pleased to advance ABP-102/CT-P72 to IND review; this reflects the strength of our T cell engager platform and the productive collaboration between Abpro and Celltrion throughout development." Miles Suk, CEO of Abpro.
• "This milestone brings us closer to delivering a potentially highly selective therapeutic candidate for patients with HER2-positive solid tumors, including those with limited treatment options." Miles Suk, CEO of Abpro.
• "It also underscores the momentum across our broader T-cell-engager platform as we continue to expand and advance a differentiated oncology pipeline." Miles Suk, CEO of Abpro.

Industry Context

The submission of an IND for a T cell engager targeting HER2-positive cancers aligns with the growing focus on immuno-oncology and targeted therapies for solid tumors. T cell engagers represent a promising class of therapeutics designed to redirect the body's immune cells to fight cancer. HER2-positive cancers, while having existing treatments, still present a significant unmet need for novel, highly selective options, especially for patients with limited treatment options. The co-development partnership with Celltrion, a leading biopharmaceutical company, also reflects a broader industry trend of strategic collaborations to accelerate drug discovery and development.

Stakeholder Impact

• Shareholders: Potential for increased value if the drug progresses successfully through clinical trials, but also exposure to significant development risks inherent in early-stage biotechnology.
• Patients: Potential for a new, highly selective therapeutic option for HER2-positive solid tumors, particularly for those with limited existing treatment options.
• Employees: Continued progress in the pipeline could provide stability and growth opportunities within the company.
• Celltrion (Co-development Partner): Continued collaboration and shared potential for success if the drug advances through clinical development and commercialization.

Next Steps

• Obtain regulatory clearance from the FDA for the IND application.
• Initiate a phase 1 clinical trial for ABP-102/CT-P72 in the first half of 2026.
• Evaluate the safety, pharmacokinetics, and preliminary efficacy of ABP-102/CT-P72 in the phase 1 study.
• Generate data from the trial to inform dose selection for future studies.
• Guide subsequent clinical development based on the data obtained from the phase 1 trial.

Key Dates

Recommendation

While the IND submission is a positive and expected milestone, it represents a very early stage in drug development. The success rate for drugs entering Phase 1 is low, and significant clinical, regulatory, and commercial hurdles remain. Investors should hold, awaiting further clinical data and a clearer path to market, while acknowledging the long-term potential and inherent risks of biotechnology investments.

Keywords

Abpro Holdings, Celltrion, IND application, FDA, ABP-102/CT-P72, HER2-positive cancers, T cell engager, phase 1 clinical trial, oncology, solid tumors, biotechnology, drug development, immuno-oncology, breast cancer, gastric cancer